| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 278 | 38.280 | 47.530 | 59.450 | 77.064 | 85.393 | 80.891 | 81.220 |
| Total Income - EUR | - | - | 278 | 38.280 | 47.530 | 59.450 | 77.064 | 85.393 | 81.213 | 81.220 |
| Total Expenses - EUR | - | - | 451 | 3.882 | 15.881 | 15.962 | 12.646 | 29.391 | 18.483 | 23.527 |
| Gross Profit/Loss - EUR | - | - | -173 | 34.398 | 31.649 | 43.488 | 64.418 | 56.002 | 62.730 | 57.694 |
| Net Profit/Loss - EUR | - | - | -182 | 33.929 | 31.173 | 42.893 | 63.647 | 55.165 | 61.934 | 55.379 |
| Employees | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Angiotop S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 1.262 | 18.216 | 12.584 | 19.560 | 13.134 | 35.062 | 30.758 |
| Current Assets | - | - | 46 | 34.357 | 63.986 | 111.527 | 102.836 | 67.527 | 55.694 | 79.543 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 8.130 | 8.106 | 8.060 |
| Receivables | - | - | 0 | 10.057 | 9.317 | 8.243 | 6.329 | 8.183 | 10.059 | 7.867 |
| Cash | - | - | 46 | 24.300 | 54.670 | 103.284 | 96.506 | 51.213 | 37.529 | 63.615 |
| Shareholders Funds | - | - | -138 | 33.793 | 24.709 | 24.241 | 23.703 | 23.777 | 85.639 | 85.161 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 183 | 1.826 | 57.493 | 99.870 | 98.692 | 56.884 | 5.117 | 25.140 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Angiotop S.r.l.